Latest gabapentin Stories
The painkiller oxycodone is effective in dulling the acute discomfort of shingles, an illness that often causes agony in sufferers, U.S.
LONDON, RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., Jan. 9 /PRNewswire-FirstCall/ -- GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S.
The drugs that cure epileptic seizures are known to increase the risk of suicide, and federal regulators decided Tuesday drug companies must clearly display that warning.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a March 31, 2008 decision by the District Court, which had found TAP Pharmaceutical Products Inc.'s U.S. Patent No. 4,628,098 valid and enforceable.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced results of a study in which Azilect(R) (rasagiline tablets) demonstrated selective MAO-B inhibition at the approved dose of 1mg. Non selective MAO inhibitors may have some contra indications with certain foods and drugs.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has entered into a settlement agreement with an institution that acted as a broker in placing investments in Teva's portfolio of auction rate securities.
Depomed, Inc. (NASDAQ:DEPO) announced today the enrollment and dosing of the first patient in Breeze 2, the second of two pivotal Phase 3 clinical trials in Depomed's registration program for DM-5689 (formerly referred to as Gabapentin GR(R)) for the treatment of menopausal hot flashes.
Depomed, Inc. (NASDAQ:DEPO) today announced that it will release third quarter financial results for 2008 after the market closes on Thursday, October 30, 2008. The company will webcast a conference call beginning at 5:00 p.m. ET, 2:00 p.m.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into a definitive agreement to sell its Israeli based veterinary business unit to Phibro Animal Health Corporation, for total consideration of approximately $47 million.
- An interdisciplinary study of social injustice.